Abstract
Chlamydia pneumoniae,such as other Chlamydia species, is an obligate intracellular parasite. To inhibit its growth it is necessary that the antimicrobial agent penetrates cells and can interfere with protein synthesis of the micro-organism. Therefore antibiotics that are likely to be active against Chlamydia pneumoniae are macrolides, tetracyclines, chloramphenicol, quinolones and rifampicin, which have demonstrated the capacity to enter cells and develop antimicrobial activity intracellularly for Chlamydia psittaci and Chlamydia trachomatis, as well as for other pathogens.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Johnson JD, Hand WL, Francis JB, King-Thompson NK, Corwin RW (1980) Antibiotic uptake by alveolar macrophages. J Lab Clin Med 95: 429–439
Prokesch RC, Hand WL (1982) Antibiotic entry into polymorphonuclear leukocytes. Antimicrob Agents Chemother 21: 373–380
Tulkens PM (1991) Intracellular pharmacokinetics and localization of antibiotics as predictors of their efficacy against intraphagocytic infections. Scand J Infect Dis [Suppl 741: 209–217
Tulkens PM (1991) Intracellular distribution and activity of antibiotics. Eur J Clin Infect Dis 10 (2): 100–106
Peters DH, Clissod SP (1992) Clarithromycin. A review of its antimicrobial activity, pharmacokinetic property and therapeutic potential. Drugs 44: 117–164
Cartier MB, Zenebergh A, Tulkens PM (1987) Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells. J Antimicrob Chemother 20 [Suppl B1: 47–56
Fraschini F, Scaglione F, Pintucci, G Maccarinelli G et al (1991) The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and in lung in humans. J Antimicrob Chemother 27 [Suppl A]: 61–65
Bergogne-Bérézin E (1993) Tissue distribution of dirithromycin: comparison with erythromycin. J Antimicrob Chemother 31 [Suppl C]: 77–87
Anderson R, Joone G, van Rensburg CEJ (1988) An in vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. J Antimicrobial Chemother 22: 923–933
MacDonald PJ, Pruul H (1991) Phagocyte uptake and transport of azithromycin. Eur J Clin Microbiol Infect Dis 10: 828–833
Foulds G, Shepard RM, Johnson RB (1990) The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 25 [Suppl A1: 73–82
Bergogne-Bérézin E (1981) Penetration of antibiotics into the respiratory tree. J Antimicrob Chemother 8: 171–174
Smith BR, LeFrock JL (1983) Bronchial tree penetration of antibiotic. Chest 83(6): 904908
Valcke Y, Pauwels R, Van Den Straeten M (1990) Pharmacokinetics of antibiotics in the lung. Eur Respir J 3: 715–722
Baldwin DR, Honeybourne D, Wise R (1992) Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents and Chemother 36 (6): 1176–1180
Gialdroni Grassi G (1980) Passaggio degli antibiotici nelle secrezioni bronchiali. In: Gialdroni Grassi G and Grassi C (eds). Aggiornamenti di chemioterapia. La Goliardica Pavese Publ., Pavia, pp 68–88
Gerdin DN, H.H.J.A (1989) Tissue penetration of the new quinolones in humans. Rev Infect Dis 11 [Suppl 5]: S1046 - S1057
Baldwin DR, Wise R, Andrews JM, Ashby JP et al (1990) Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J 3: 886–890
Andrews JM, Honeybourne D, Greaves I, Baldwin D et al (1992) Clarithromycin levels in human bronchial mucosa, alveolar macrophages and serum. 8th Mediterranean Congress of Chemotherapy Athens, Greece Abs. 714
Baldwin DR, Honeybourne D, Wise R (1992) Pulmonary disposition of antimicrobial agents: methodological consideration. Antimicrob Agents Chemother 36: 1171–1175
Gump DW (1991) Antimicrobial susceptibility testing for some atypical microrganisms: Chlamydiae, Mycoplasms, Rickettsia, and Spirochetes. In: Lorian V (ed) Antibiotic in laboratory medicine. 3rd Ed, Williams & Wilkins, pp 279–294
Welsh LE, Gaydos CA, Quinn TC (1992) In vitro evaluation of activities of azithromycin, erythromycin and tetracyclines against Chlamydia trachomatis and Chlamydia pneumoniae Antimicrob Agents Chemother 36:291–294
Cooper MA, Baldwin D, Matthews RS, Andrews JM, Wise R (1991) In vitro susceptibility of Chlamydia pneumoniae ( TWAR) to seven antibiotics. J Antimicrob Chemother 2: 407–413
Roblin PM, Hammerschlag MR (1990) In vitro activity of sparfloxacin (CI-978, AT 4140) and other quinolones against Chlamydia trachomatis and Chlamydia pneumoniae. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, Atlanta Abs 22
Kuo CC, Grayston JT (1988) In vitro drug susceptibility of Chlamydia sp. strain TWAR. Antimicrob Agents Chemother 32:257–258
Atmar RL, Greenberg SB (1989) Pneumonia caused by Mycoplasma pneumoniae and the TWAR agent. Seminars in Respiratory Infections 4: 19–31
Bourke SJ (1993) Chlamydial respiratory infections. British Med J 306: 1219–1220
Fenelon LE, Mumtaz G, Ridgway GL (1990) The in vitro susceptibility of Chlamydia pneumoniae. J Antimicrob Chemother 26: 763–767
Chirwing K, Roblin PM, Hammerschlag MR (1989) In vitro susceptibilities of Chlamydia pneumoniae Antimicrob Agents Chemother 1634–1635
Orfila J, Haider F (1992) In vitro susceptibilities of Chlamydia pneumoniae strain IOL 207 against clarithromycin, compared to different molecules. In: Adam D, Lode H, Rubinstein E (eds) Recent Advances in Chemotherapy. Proceedings of the 17th International Congress of Chemotherapy Berlin, Futuramed Publisher, Munich, Germany, pp 2454–2455
Hammerschlag MR, Qumei KK, Roblin PM (1992) In vitro activities of azithromycin, clarithromycin, L-ofloxacin and other antibiotics against Chlamydia pneumoniae Antimicrob Agents Chemother 36:1573–1574
Soejima R, Niki Y, Kishimoto T, Kimura M, Kubota Y (1994) Anti-chlamydial activities of newly developed fluoroquinolones and their clinical usefulness for Chlamydia respiratory infections. 5th Int Symposium on new quinolones, Singapore, Abs 135
Ridgway GL, Mumtaz G, Fenelon L (1991) In vitro activity of clarithromycin and other macrolides against the type strain of Chlamydia pneumoniae J Antimicrob Chemother 27 [Suppl A1:43–45
Roblin PM, Montalban G, Hammerschlag MR (1994) Susceptibilities of isolates of Chlamydia pneumoniae from children with pneumonia to clarithromycin and erythromycin. 2nd International Conference on the macrolides, azalides and streptogamins, Venice, Italy, Abs 150
Orfila F, Haider F (1990) In vitro susceptibility of Chlamydia pneumoniae (strain IOL 207) against a new fluoroquinolone, sparfloxacin, compared to different other molecules. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, Atlanta, Georgia, October 21–24, 1990, Abs 18
Hammerschlag MR, Hyman CL, Roblin PM (1992) In vitro activities of five quinolones against Chlamydia pneumoniae Antimicrob Agents Chemother 36:682–683
Orfila J, Haider F (1992) In vitro susceptibility of Chlamydia pneumoniae strain IOL 207 against temafloxacin compared to different other molecules. In: Adam D, Lode H, Rubinstein E (eds) Recent Advances in Chemotherapy. Proceedings of the 17th International Congress of Chemotherapy, Berlin 1991, vol II, pp 2344–45, Futuramed Publisher, Munich, Germany
Andrews JM, Wise R, Brenwald N (1993) In vitro activity of BAY3118. VI Eur Congress Clin Microbiol and Infect Dis, Seville, March 28–31, 1993, Abs 4
Roblin PM, Montalban G, Hammerschlag MR (1994) In vitro activities of OPC-17116, a new quinolone, ofloxacin and sparfloxacin against Chlamydia pneumoniae Antimicrob Agents Chemother 38:1402–1403
Dumornay W, Mandel L, Smith P, Schacter J (1992) Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis 14: 178–182
Kobayashi H (1986) Clinical evaluation of ofloxacin in lower respiratory tract infections. Infection 14 [Suppl4]: S279–5282
Lipsky BA, Tack KJ, Kuo CC, Wang SP (1990) Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. Am J Med 89: 722–724
Nakata K, Okazaki Y, Hattori H, Nakamura S (1994) Protective effect of sparfloxacin in experimental pneumonia caused by Chlamydia pneumoniae in leukopenic mice. Antimicrob Agents Chemother 38: 1757–1762
Aubier M, Garau J, Geslin P, Grassi C, Hosie G, Huchon G, Legakis N, Lode H, Regamey C and the European Study Group (1994) Sparfloxacin: an empiric therapy in community-acquired pneumonia. A meta-analysis of two comparative studies. 6th Int Congress for Infect Dis, Prague, April 26–30, 1994, Abs 459
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag Italia, Milano
About this chapter
Cite this chapter
Grassi, G.G. (1995). Pharmacological and Pharmacokinetic Basis of Chlamydia pneumoniae Treatment. In: Allegra, L., Blasi, F. (eds) Chlamydia Pneumoniae Infection. Springer, Milano. https://doi.org/10.1007/978-88-470-2201-0_5
Download citation
DOI: https://doi.org/10.1007/978-88-470-2201-0_5
Publisher Name: Springer, Milano
Print ISBN: 978-3-540-75007-9
Online ISBN: 978-88-470-2201-0
eBook Packages: Springer Book Archive